BMCM
BIO icon

Burns Matteson Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Burns Matteson Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,336
Closed -$661K – 124
2022
Q2 		$661K Buy
+1,336
New +$696K 0.46% 57
2021
Q3 		– Sell
-627
Closed -$404K – 137
2021
Q2 		$404K Buy
+627
New +$382K 0.32% 60

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Burns Matteson Capital Management's BIO Position: Q3 2022 in Review

Burns Matteson Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 1,336 shares — an estimated $661K sold.

Burns Matteson Capital Management first reported a position in BIO in Q2 2021 and held it in 2 quarters. The position peaked at $661K in Q2 2022. 484 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Burns Matteson Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Burns Matteson Capital Management sold 1,336 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $661K.
  • Burns Matteson Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 2 quarters.
  • Burns Matteson Capital Management's Bio-Rad Laboratories Class A position peaked at $661K in Q2 2022.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Burns Matteson Capital Management's 13F filing for Q3 2022, filed 12 Dec 2023.